China SXT Pharmaceuticals, Inc. (SXTC)
| Market Cap | 54.18K -100.0% |
| Revenue (ttm) | 1.14M -34.6% |
| Net Income | -6.21M |
| EPS | n/a |
| Shares Out | 1.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,741,487 |
| Open | 0.0421 |
| Previous Close | 0.0480 |
| Day's Range | 0.0381 - 0.0455 |
| 52-Week Range | 0.0381 - 83,758.3310 |
| Beta | 1.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2019 |
About SXTC
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It pr... [Read more]
Financial Performance
In fiscal year 2026, China SXT Pharmaceuticals's revenue was $1.14 million, a decrease of -34.63% compared to the previous year's $1.74 million. Losses were -$6.21 million, 87.8% more than in 2025.
Financial StatementsNews
China SXT Pharmaceuticals Inc trading halted, news pending
19:50 EDT China SXT Pharmaceuticals (SXTC) Inc trading halted, news pending
China SXT Pharmaceuticals implementing 1-for-100 share consolidation
China SXT Pharmaceuticals (SXTC) will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26. The…
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, ...
China SXT Pharmaceuticals announces termination of additional purchase right
China SXT Pharmaceuticals (SXTC) announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026. Under the termina...
China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers...
China SXT Pharmaceuticals announces $12M registered direct offering
China SXT Pharmaceuticals (SXTC) announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8M Class A ordinary…
3 Penny Stocks to Watch Today, October 8
China SXT Pharmaceuticals ($SXTC), Baiya International Group ($BIYA), and Lipocine Inc. ($LPCN) are among the penny stocks to watch on October 8, according to TipRanks’ Penny Stock Screener Tool. A pe...
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional i...
China SXT Pharmaceuticals Inc trading halted, news pending
19:50 EDT China SXT Pharmaceuticals (SXTC) Inc trading halted, news pending
China SXT Pharmaceuticals announces share consolidation
China SXT Pharmaceuticals (SXTC) announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par…
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, tod...
China SXT Pharmaceuticals prices 4.5M units at $2.00 in registered direct offer
China SXT Pharmaceuticals (SXTC) announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4.5M un...
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement wit...
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, ma...
China SXT Pharmaceuticals Inc trading halted, news pending
19:50 EST China SXT Pharmaceuticals (SXTC) Inc trading halted, news pending
Here’s Why China SXT Pharmaceuticals Stock (SXTC) Rocketed Today
China SXT Pharmaceuticals stock was up ahead of the company’s reverse stock split tomorrow.
China SXT Pharmaceuticals announces 1-for-150 share consolidation
China SXT Pharmaceutics announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026. The Company’s Class A ordinary…
China SXT announces initiative to apply AI tech across TCM supply chain
China SXT Pharmaceuticals (SXTC) announced as part of its Artificial Intelligence Insight Initiative to explore the application of Artificial Intelligence and related digital technologies across the T...
Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, tod...
China SXT Pharmaceuticals announces $10M registered direct offering
China SXT Pharmaceuticals (SXTC) announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66.67M Class A ordinary…
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor ...
Why Is Penny Stock China SXT (SXTC) Up Almost 200% Today?
Shares in China SXT Pharmaceuticals ($SXTC) staged a massive rally on Thursday afternoon after the Chinese traditional medicine company launched an initiative to integrate artificial intelligence-driv...
China SXT announces launch of Strategic AI Insights Initiative
China SXT Pharmaceuticals (SXTC) announced the launch of a Strategic Artificial Intelligence (AI) Insights Initiative. This initiative aims to integrate AI-driven analytics into the Company’s product ...
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency
TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company focusing on the research, development, manufactur...
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on October 3, 2024, the Company received a notificati...